View Older Stories View More Recent Stories
-
Inventiva SA (IVA) PT Lowered to $14 at H.C. Wainwright
-
Travere Therapeutics (TVTX) PT Lowered to $18 at H.C. Wainwright
-
H.C. Wainwright Reiterates Neutral Rating on Durect Corp (DRRX)
-
H.C. Wainwright Reiterates Neutral Rating on Assembly Biosciences (ASMB)
-
H.C. Wainwright Reiterates Buy Rating on Genfit (GNFT)
-
H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)
-
H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO)
-
H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX)
-
H.C. Wainwright Reiterates Buy Rating on Iterum Therapeutics (ITRM)
-
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
-
H.C. Wainwright Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH)
-
Travere Therapeutics (TVTX) PT Raised to $23 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
H.C. Wainwright Starts Aligos Therapeutics Inc. (ALGS) at Buy
-
Unicycive Therapeutics (UNCY) PT Lowered to $2.50 at H.C. Wainwright
-
Iterum Therapeutics (ITRM) PT Lowered to $5 at H.C. Wainwright
-
H.C. Wainwright Upgrades Cidara Therapeutics (CDTX) to Buy
-
Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
-
Arcturus Therapeutics (ARCT) PT Raised to $63 at H.C. Wainwright
-
Ardelyx, Inc (ARDX) PT Raised to $11 at H.C. Wainwright
-
Mirum Pharmaceuticals (MIRM) said approached by Sobi about a takeover - source
-
H.C. Wainwright Reiterates Buy Rating on Ardelyx, Inc (ARDX)
-
H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX)
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
Ardelyx, Inc (ARDX) PT Lowered to $10 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
H.C. Wainwright Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharamceuticals (MIRM) PT Raised to $66 at H.C. Wainwright
-
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
-
H.C. Wainwright Reiterates Neutral Rating on Durect Corp (DRRX)
-
89bio Inc. (ETNB) PT Lowered to $29 at H.C. Wainwright
-
Enanta Pharmaceuticals (ENTA) PT Lowered to $27 at H.C. Wainwright
-
Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright
-
Travere Therapeutics (TVTX) PT Raised to $19 at H.C. Wainwright
-
Akebia Therapeutics (AKBA) PT Raised to $6 at H.C. Wainwright, 'favorable label to daprodustat'
-
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
-
Mirum Pharamceuticals (MIRM) PT Raised to $58 at H.C. Wainwright
-
Ardelyx, Inc (ARDX) PT Raised to $13 at H.C. Wainwright
-
H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy
-
H.C. Wainwright Downgrades Durect Corp (DRRX) to Neutral, 'AHFIRM disappoints'
-
H.C. Wainwright Starts ZyVersa Therapeutics, Inc. (ZVSA) at Buy, 'We Uncover Two Diamonds in the Rough'
-
H.C. Wainwright Starts Ardelyx, Inc (ARDX) at Buy 'Ahead of the potential approval of XPHOZAH next quarter'
-
H.C. Wainwright Upgrades Akebia Therapeutics (AKBA) to Buy, 'What we have been waiting for'
-
H.C. Wainwright Double Upgrades Intercept Pharmaceuticals (ICPT) to Buy
-
Intercept Pharma (ICPT) cut to sell as FDA advisory committee votes to defer NDA approval
-
H.C. Wainwright Downgrades Intercept Pharmaceuticals (ICPT) to Sell
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
-
H.C. Wainwright Upgrades Arcturus Therapeutics (ARCT) to Buy, 'Expecting ARCT-154 Approval in Japan As COVID-19 Vaccine and Booster in 2023'
-
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

